Open AccessCOVID-19 in a patient with severe asthma using mepolizumab
Author(s) -
Kurtuluş Aksu,
Selma Yeşilkaya,
Musa Topel,
Süleyman Türkyılmaz,
Dilek Çuhadar Erçelebi,
Ali Öncül,
İlkay Koca Kalkan,
Hale Ateş
Publication year - 2021
Publication title -
allergy and asthma proceedings
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.643
H-Index - 60
eISSN - 1539-6304
pISSN - 1088-5412
DOI - 10.2500/aap.2021.42.200125
Subject(s) - mepolizumab , medicine , asthma , omalizumab , adverse effect , dupilumab , covid-19 , allergy , immunology , disease , immunoglobulin e , antibody , eosinophil , infectious disease (medical specialty)
Background: There is a lack of information about the course of coronavirus disease 2019 (COVID-19) in patients with severe asthma who were treated with biologics. Some reports indicated that treatment with benralizumab, dupilumab, and omalizumab in patients with severe asthma was not associated with significant adverse effects during COVID-19. Methods: Asthma itself or the biologic agents used to treat asthma can have a positive effect on the course of COVID-19. There seem not to be any cases that specifically reported the use of mepolizumab in a patient who was infected with COVID. Results: We reported of a 55-year-old woman with a diagnosis of severe asthma for; 3 years and who was being treated with mepolizumab, with no evidence of loss of asthma control, at the time of contracting COVID-19 and who had been followed up in the allergy clinic. In addition, there are no data on mepolizumab therapy in patients with elevated liver enzyme levels. Conclusion: With this case, we also reported that no adverse effects were observed during mepolizumab treatment in a patient with elevated liver enzyme levels.